Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 fostamatinib versus placebo in warm autoimmune hemolytic anemia
NL-OMON52459Phase 3Active, not recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing Fostamatinib with Placebo (2 arms). Primary endpoint: Durable hemoglobin response. Started Aug 2020; status: active, not recruiting.
02
Drugs
fostamatinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON52459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52459.